Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort

被引:14
|
作者
Horn-Ross, Pamela L. [1 ]
Canchola, Alison J. [1 ]
Bernstein, Leslie [3 ]
Neuhausen, Susan L. [3 ]
Nelson, David O. [2 ]
Reynolds, Peggy [2 ,4 ]
机构
[1] Canc Prevent Inst Calif, 2201 Walnut Ave,Suite 300, Fremont, CA 94538 USA
[2] Canc Prevent Inst Calif, 2001 Ctr St,Suite 700, Berkeley, CA 94704 USA
[3] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, 1500 Duarte Rd, Duarte, CA 91010 USA
[4] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Div Epidemiol, 150 Governors Lane, Stanford, CA 94305 USA
来源
BREAST CANCER RESEARCH | 2016年 / 18卷
关键词
Breast cancer; Body size; Obesity; Adiposity; Body fat distribution; Height; Life course; ADULT WEIGHT CHANGE; NEW-YORK; WOMEN; PREMENOPAUSAL; PROGESTIN; ADIPOSITY; HEALTH; SHAPE;
D O I
10.1186/s13058-016-0790-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Obesity is a public health epidemic and an important breast cancer risk factor. The relationship between interrelated body measurements is complex and most studies fail to account for this complexity. We identified key aspects of body size which jointly, over the life-course (since adolescence), are associated with estrogen-receptor-positive (ER+) breast cancer risk. Methods: Among 109,862 women participating in the California Teachers Study cohort, 3844 were diagnosed with invasive ER+ breast cancer between 1997-1998 and December 2011. Based on validated self-reported height and weight at age 18, baseline, and 10-year follow up and waist circumference at 2-year and 10-year follow up, we identified 16 a priori body-size phenotypes. Multivariable Cox proportional hazards models provided estimates of hazard rate ratios (HR) and 95% confidence intervals (CI). Results: Premenopausal breast cancer was influenced by adolescent, but not adult, body size (HR = 0.51, 95% CI 0. 31-0.86 for body mass index (BMI; kg/m(2)) >= 25 vs < 20 at age 18). Among postmenopausal women currently using hormone therapy, only those with the greatest body size had increased breast cancer risk (HR = 1.36, 95% CI 1.13-1. 64 for height >= 67 inches and adult BMI >= 25 vs height < 67). Among postmenopausal women not currently using hormone therapy, the relationship between body size and risk was complex, with the largest effects of adiposity among short women. Among short women, those with gluteal adiposity (HR = 2.70, 95% CI 1.77-4.10) and those who continued to gain weight throughout adulthood (HR = 2.57, 95% CI 1.60-4.12) were at greatest risk, whereas those who had been overweight/obese since adolescence were not at increased risk (HR = 1.33, 95% CI 0.84-2.10). Height was associated with a small increased risk, with borderline statistical significance. Conclusions: Considering absolute body mass in adolescence and at two points in adulthood, dynamic changes in adiposity over time, and body fat distribution, we identified obesity phenotypes associated with ER+ breast cancer risk. Our approach more clearly identifies specific risk groups than do analyses that evaluate similar measures separately. These findings may aid in improving risk prediction models and developing targeted interventions, and may clarify inconsistent findings across studies.
引用
收藏
页数:13
相关论文
共 50 条
  • [11] Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort
    Canchola, Alison J.
    Chang, Ellen T.
    Bernstein, Leslie
    Largent, Joan A.
    Reynolds, Peggy
    Deapen, Dennis
    Henderson, Katherine D.
    Ursin, Giske
    Horn-Ross, Pamela L.
    CANCER CAUSES & CONTROL, 2010, 21 (12) : 2241 - 2248
  • [12] Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort
    Alison J. Canchola
    Ellen T. Chang
    Leslie Bernstein
    Joan A. Largent
    Peggy Reynolds
    Dennis Deapen
    Katherine D. Henderson
    Giske Ursin
    Pamela L. Horn-Ross
    Cancer Causes & Control, 2010, 21 : 2241 - 2248
  • [13] High-Risk Estrogen-Receptor-Positive Breast CancerIdentification and Implications for Therapy
    Rosemary L. Balleine
    Nicholas R. Wilcken
    Molecular Diagnosis & Therapy, 2012, 16 : 235 - 240
  • [14] Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow
    Johanna M. Buschhaus
    Brock A. Humphries
    Samantha S. Eckley
    Tanner H. Robison
    Alyssa C. Cutter
    Shrila Rajendran
    Henry R. Haley
    Avinash S. Bevoor
    Kathryn E. Luker
    Gary D. Luker
    Oncogene, 2020, 39 : 5649 - 5662
  • [15] Case 24-2005: A woman with estrogen-receptor-positive breast cancer
    Denes, AE
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (21): : 2304 - 2304
  • [16] Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow
    Buschhaus, Johanna M.
    Humphries, Brock A.
    Eckley, Samantha S.
    Robison, Tanner H.
    Cutter, Alyssa C.
    Rajendran, Shrila
    Haley, Henry R.
    Bevoor, Avinash S.
    Luker, Kathryn E.
    Luker, Gary D.
    ONCOGENE, 2020, 39 (34) : 5649 - 5662
  • [17] Prediction of late relapse in patients with estrogen-receptor-positive breast cancer.
    Buechler, Steven
    Badve, Sunil S.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [18] Dietary patterns and breast cancer risk in the California Teachers Study cohort
    Link, Lilli B.
    Canchola, Alison J.
    Bernstein, Leslie
    Clarke, Christina A.
    Stram, Daniel O.
    Ursin, Giske
    Horn-Ross, Pamela L.
    AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 98 (06): : 1524 - 1532
  • [19] NEURO-ENDOCRINE ABNORMALITIES AND THE PATHOGENESIS OF ESTROGEN-RECEPTOR-POSITIVE BREAST-CANCER
    LEHRER, S
    BROWN, RR
    LEE, C
    KALNICKI, S
    LIPSZTEIN, R
    BLOOMER, WD
    MOUNT SINAI JOURNAL OF MEDICINE, 1988, 55 (04): : 272 - 275
  • [20] Androgen receptor (AR) agonists inhibit AR- and estrogen-receptor-positive breast cancer
    Asemota, Sarah
    Ponnusamy, Suriyan
    Thiyagarajan, Thirumagal
    Narayanan, Ramesh
    CANCER RESEARCH, 2022, 82 (12)